The prevalence of TP53 mutation and primary resistance mechanisms in short-term responders to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.

e21237Background: Non-small cell lung cancer (NSCLC) with activating EGFR mutations in exon 19 or 21 usually responds to EGFR tyrosine kinase inhibitors (TKIs), but sometimes the responses can only...